Jiangsu Hengrui Medicine Co., Ltd.
600276
Classifica tra le azioni
#544
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Prezzo delle azioni
$6.89
Capitalizzazione di mercato
$43.94B
Variazione (1 giorno)
-2.91%
Variazione (1 anno)
-24.78%
Paese
CN
Scambia Jiangsu Hengrui Medicine Co., Ltd. (600276)
Categoria
Healthcare
Rapporto P/S per Jiangsu Hengrui Medicine Co., Ltd. (600276)
Rapporto P/S al October 2026 TTM: 9.37
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Jiangsu Hengrui Medicine Co., Ltd., il rapporto P/S attuale (TTM) è 9.37. Alla fine del 2024, era pari a 10.39.
Storico del rapporto P/S per Jiangsu Hengrui Medicine Co., Ltd. da 2001 a 2026
Rapporto P/S alla fine di ogni anno
| Anno | Rapporto P/S | Cambia |
|---|---|---|
| 2026 (TTM) | 9.37 | -23.96% |
| 2025 | 12.32 | 18.54% |
| 2024 | 10.39 | -17.13% |
| 2023 | 12.54 | 8.76% |
| 2022 | 11.53 | -7.68% |
| 2021 | 12.49 | -41.32% |
| 2020 | 21.29 | 28.72% |
| 2019 | 16.54 | 47.69% |
| 2018 | 11.20 | -3.36% |
| 2017 | 11.59 | 44.55% |
| 2016 | 8.02 | -6.62% |
| 2015 | 8.58 | 63.97% |
| 2014 | 5.24 | -9.71% |
| 2013 | 5.80 | 21.57% |
| 2012 | 4.77 | -5.76% |
| 2011 | 5.06 | -38.70% |
| 2010 | 8.26 | 10.18% |
| 2009 | 7.49 | 29.72% |
| 2008 | 5.78 | -34.42% |
| 2007 | 8.81 | 78.87% |
| 2006 | 4.92 | 420.22% |
| 2005 | 0.95 | 14.31% |
| 2004 | 0.83 | -8.27% |
| 2003 | 0.90 | -28.02% |
| 2002 | 1.25 | -16.11% |
| 2001 | 1.50 | 0.00% |
Rapporto P/S per aziende simili o concorrenti
| Azienda | Rapporto P/S | Differenza del rapporto P/S | Il paese |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| 2.19 | -76.66% |
JP
|
|
| - | - |
CH
|
|
| 7.06 | -24.66% |
IN
|
